Resveratrol inhibits pathologic retinal neovascularization in Vldlr-/- Mice

Investigative Ophthalmology and Visual Science

Volumn 52, Issue 5, 2011, Pages 2809-2816

  Hua, Jing ^a   Guerin, Karen I ^a   Chen, Jing ^a   Michán, Shaday ^b,c   Stahl, Andreas ^a,d   Krah, Nathan M ^a   Seaward, Molly R ^a   Dennison, Roberta J ^a   Juan, Aimee M ^a   Hatton, Colman J ^a   Sapieha, Przemyslaw ^a,e   Sinclair, David A ^b   Smith, Lois E H ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c INSTITUTO NACIONAL DE GERIATRÍA   (Mexico)

^d UNIVERSITY OF FREIBURG   (Germany)

^e UNIVERSITY OF MONTREAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; RESVERATROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG MECHANISM; DRUG RESPONSE; ENDOTHELIUM CELL; GENE; GENE REPRESSION; GFAP GENE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PERINATAL PERIOD; PHOTORECEPTOR; PRIORITY JOURNAL; RETINA; RETINA NEOVASCULARIZATION; RETINAL TELANGIECTASIA; RHODOPSIN GENE; SIGNAL TRANSDUCTION; UPREGULATION; VEGF GENE; VLDLR GENE;

ADMINISTRATION, ORAL; ANGIOGENESIS INHIBITORS; ANIMALS; ANTIOXIDANTS; BLOTTING, WESTERN; DISEASE MODELS, ANIMAL; ENDOTHELIUM, VASCULAR; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NERVE TISSUE PROTEINS; RECEPTORS, LDL; RETINA; RETINAL NEOVASCULARIZATION; RETINAL TELANGIECTASIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; STILBENES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79956045392     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.10-6496     Document Type: Article

References (41)

1. Klein R, Peto T, Bird A, Vannewkirk MR. The epidemiology of age-related macular degeneration. Am J Ophthalmol. 2004;137: 486-495.
2. Chew E, Gillies M, Bird A. Macular telangiectasia: a simplified classification. Arch Ophthalmol. 2006;124:573-574.
3. Gass JD. Histopathologic study of presumed parafoveal telangiectasis. Retina. 2000;20:226-227.
4. Yannuzzi LA, Bardal AM, Freund KB, Chen KJ, Eandi CM, Blodi B. Idiopathic macular telangiectasia. Arch Ophthalmol. 2006;124: 450-460.
5. Heckenlively JR, Hawes NL, Friedlander M, et al. Mouse model of subretinal neovascularization with choroidal anastomosis. Retina. 2003;23:518-522.
6. Dorrell MI, Aguilar E, Jacobson R, et al. Antioxidant or neurotrophic factor treatment preserves function in a mouse model of neovascularization-associated oxidative stress. J Clin Invest. 2009; 119:611-623.
7. Hu W, Jiang A, Liang J, et al. Expression of VLDLR in the retina and evolution of subretinal neovascularization in the knockout mouse model's retinal angiomatous proliferation. Invest Ophthalmol Vis Sci. 2008;49:407-415.
8. Li C, Huang Z, Kingsley R, et al. Biochemical alterations in the retinas of very low-density lipoprotein receptor knockout mice: an animal model of retinal angiomatous proliferation. Arch Ophthalmol. 2007;125:795-803.
9. Chen Y, Hu Y, Moiseyev G, Zhou KK, Chen D, Ma JX. Photoreceptor degeneration and retinal inflammation induced by very low-density lipoprotein receptor deficiency. Microvasc Res. 2009; 78:119-127.
10. Chen Y, Hu Y, Lu K, Flannery JG, Ma JX. Very low density lipoprotein receptor, a negative regulator of the wnt signaling pathway and choroidal neovascularization. J Biol Chem. 2007;282: 34420-34428.
11. Hung LM, Chen JK, Huang SS, Lee RS, Su MJ. Cardioprotective effect of resveratrol, a natural antioxidant derived from grapes. Cardiovasc Res. 2000;47:549-555.
12. Igura K, Ohta T, Kuroda Y, Kaji K. Resveratrol and quercetin inhibit angiogenesis in vitro. Cancer Lett. 2001;171:11-16.
13. Tseng SH, Lin SM, Chen JC, et al. Resveratrol suppresses the angiogenesis and tumor growth of gliomas in rats. Clin Cancer Res. 2004;10:2190-2202.
14. Brakenhielm E, Cao R, Cao Y. Suppression of angiogenesis, tumor growth, and wound healing by resveratrol, a natural compound in red wine and grapes. FASEB J. 2001;15:1798-1800.
15. Kaga S, Zhan L, Matsumoto M, Maulik N. Resveratrol enhances neovascularization in the infarcted rat myocardium through the induction of thioredoxin-1, heme oxygenase-1 and vascular endothelial growth factor. J Mol Cell Cardiol. 2005;39:813-822.
16. Dong W, Li N, Gao D, Zhen H, Zhang X, Li F. Resveratrol attenuates ischemic brain damage in the delayed phase after stroke and induces messenger RNA and protein express for angiogenic factors. J Vasc Surg. 2008;48:709-714.
17. Hsieh YH, Huang SS, Wei FC, Hung LM. Resveratrol attenuates ischemia-reperfusion-induced leukocyte-endothelial cell adhesive interactions and prolongs allograft survival across the MHC barrier. Circ J. 2007;71:423-428.
18. Frykman PK, Brown MS, Yamamoto T, Goldstein JL, Herz J. Normal plasma lipoproteins and fertility in gene-targeted mice homozygous for a disruption in the gene encoding very low density lipoprotein receptor. Proc Natl Acad Sci U S A. 1995;92:8453-8457.
19. Baur JA, Pearson KJ, Price NL, et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature. 2006;444:337-342.
20. Milne JC, Lambert PD, Schenk S, et al. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature. 2007;450:712-716.
21. Bellacen K, Lewis EC. Aortic ring assay. J Vis Exp. 2009;33. pii: 1564.
22. Zhu WH, Iurlaro M, MacIntyre A, Fogel E, Nicosia RF. The mouse aorta model: influence of genetic background and aging on bFGFand VEGF-induced angiogenic sprouting. Angiogenesis. 2003;6: 193-199.
23. Sapieha P, Sirinyan M, Hamel D, et al. The succinate receptor GPR91 in neurons has a major role in retinal angiogenesis. Nat Med. 2008;14:1067-1076.
24. Lofqvist C, Chen J, Connor KM, et al. IGFBP3 suppresses retinopathy through suppression of oxygen-induced vessel loss and promotion of vascular regrowth. Proc Natl Acad Sci U S A. 2007;104: 10589-10594.
25. LaMontagne KR Jr, Moses MA, Wiederschain D, et al. Inhibition of MAP kinase kinase causes morphological reversion and dissociation between soft agar growth and in vivo tumorigenesis in angiosarcoma cells. Am J Pathol. 2000;157:1937-1945.
26. Kovach JL, Rosenfeld PJ. Bevacizumab (avastin) therapy for idiopathic macular telangiectasia type II. Retina. 2009;29:27-32.
27. Gamulescu MA, Walter A, Sachs H, Helbig H. Bevacizumab in the treatment of idiopathic macular telangiectasia. Graefes Arch Clin Exp Ophthalmol. 2008;246:1189-1193.
28. Charbel Issa P, Finger RP, Holz FG, Scholl HP. Eighteen-month follow-up of intravitreal bevacizumab in type 2 idiopathic macular telangiectasia. Br J Ophthalmol. 2008;92:941-945.
29. Meyerle CB, Freund KB, Iturralde D, et al. Intravitreal bevacizumab (Avastin) for retinal angiomatous proliferation. Retina. 2007;27: 451-457.
30. Joeres S, Heussen FM, Treziak T, Bopp S, Joussen AM. Bevacizumab (Avastin) treatment in patients with retinal angiomatous proliferation. Graefes Arch Clin Exp Ophthalmol. 2007;245:1597-1602.
31. Costagliola C, Romano MR, dell'Omo R, Cipollone U, Polisena P. Intravitreal bevacizumab for the treatment of retinal angiomatous proliferation. Am J Ophthalmol. 2007;144:449-451.
32. Lai TY, Chan WM, Liu DT, Lam DS. Ranibizumab for retinal angiomatous proliferation in neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2007;245:1877-1880.
33. Konstantinidis L, Mameletzi E, Mantel I, Pournaras JA, Zografos L, Ambresin A. Intravitreal ranibizumab (Lucentis) in the treatment of retinal angiomatous proliferation (RAP). Graefes Arch Clin Exp Ophthalmol. 2009;247:1165-1171.
34. Nishijima K, Ng YS, Zhong L, et al. Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am J Pathol. 2007;171:53-67.
35. Koizumi H, Slakter JS, Spaide RF. Full-thickness macular hole formation in idiopathic parafoveal telangiectasis. Retina. 2007;27: 473-476.
36. Khan AA, Dace DS, Ryazanov AG, Kelly J, Apte RS. Resveratrol regulates pathologic angiogenesis by a eukaryotic elongation factor-2 kinase-regulated pathway. Am J Pathol. 2010;177:481-492.
37. Fremont L. Biological effects of resveratrol. Life Sci. 2000;66:663-673.
38. Park DW, Baek K, Kim JR, et al. Resveratrol inhibits foam cell formation via NADPH oxidase 1-mediated reactive oxygen species and monocyte chemotactic protein-1. Exp Mol Med. 2009; 41:171-179.
39. Yousuf S, Atif F, Ahmad M, et al. Resveratrol exerts its neuroprotective effect by modulating mitochondrial dysfunctions and associated cell death during cerebral ischemia. Brain Res. 2009; 1250:242-253.
40. Sebai H, Gadacha W, Sani M, Aouani E, Ghanem-Boughanmi N, Ben-Attia M. Protective effect of resveratrol against lipopolysaccharide-induced oxidative stress in rat brain. Brain Injury. 2009;23: 1089-1094.
41. King RE, Kent KD, Bomser JA. Resveratrol reduces oxidation and proliferation of human retinal pigment epithelial cells via extracellular signal-regulated kinase inhibition. Chem-Biol Interactions. 2005;151:143-149.